ClinicalTrials.gg
Not yet recruitingNCT07853391Updated Oct 1, 2026

Predictors of Outcomes of Convulsive Status Epilepticus

An observational study in Status Epilepticus and Convulsive Status Epilepticus, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Assiut University · Observational

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Status epilepticus is a life-threatening neurological emergency characterized by prolonged seizures or multiple seizures occurring without the patient regaining consciousness between episodes. Convulsive status epilepticus is associated with high rates of morbidity and mortality if not promptly recognized and controlled. While prognostic factors have been studied in various populations, data regarding clinical predictors and hospital outcomes in Upper Egypt remain limited.

The purpose of this prospective, hospital-based observational study is to identify the clinical predictors of short-term outcomes among adult patients presenting with convulsive status epilepticus admitted to Assiut University Hospitals.

All eligible participants aged 18 years and older admitted with convulsive status epilepticus will receive standard-of-care medical management according to institutional clinical protocols. Researchers will systematically collect clinical data, including demographic factors, seizure semiology and duration, underlying etiologies, laboratory tests, neuroimaging findings, and electroencephalography (EEG) results.

Participants will be followed throughout their hospital stay to assess functional outcome at discharge using the Modified Rankin Scale (mRS), in-hospital mortality, response to antiseizure treatment, development of refractory or super-refractory status epilepticus, requirement for intensive care unit (ICU) admission or mechanical ventilation, and length of hospital stay.

02

Conditions studied

  • Status Epilepticus
  • Convulsive Status Epilepticus

Browse trials for

Keywords

  • Convulsive status epilepticus
  • Predictors of outcome
  • Refractory status epilepticus
  • Super-refractory status epilepticus
  • In-hospital mortality
  • Modified Rankin Scale
  • Seizure control
  • Mechanical ventilation
  • Intensive care unit
03

In context

Status Epilepticus

124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.

This study's planned enrollment of 100 is below the median of 156 across 42 observational studies indexed under Status Epilepticus.

Browse Status Epilepticus studies →

Lead sponsor

Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Adult patients presenting with convulsive status epilepticus admitted to the emergency, neurology, or intensive care departments at Assiut University Hospitals. The population includes individuals aged 18 years and older presenting with continuous convulsive seizure activity lasting more than 5 minutes or two or more discrete seizures without full recovery of consciousness between episodes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Presentation with convulsive status epilepticus, defined as continuous convulsive seizure activity lasting more than 5 minutes or two or more discrete seizures without full recovery of consciousness between episodes.

Exclusion criteria

Exclusion Criteria:

  • Functional or dissociative (psychogenic non-epileptic) status.
  • Acute cardiac arrest with motor phenomena due to cerebral anoxia.
  • Movement disorders mimicking seizures (e.g., acute extrapyramidal side effects, chorea, or dyskinesias).
  • Age younger than 18 years.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Convulsive Status Epilepticus Cohort

    Adult patients (aged 18 years and older) admitted to Assiut University Hospitals presenting with convulsive status epilepticus, defined as continuous convulsive seizure activity lasting more than 5 minutes or two or more discrete seizures without full recovery of consciousness between episodes. All enrolled participants receive standard-of-care medical management according to institutional guidelines, including first- and second-line antiseizure medications, anesthetic agents, and intensive care or mechanical ventilation when clinically required. Demographic characteristics, clinical features, etiology, laboratory investigations, neuroimaging, electroencephalography (EEG), and treatment responses are prospectively collected throughout hospitalization until discharge to determine clinical predictors of outcome.

06

What researchers measure

Primary outcomes

  1. Modified Rankin Scale Score

    Functional outcome assessed using the Modified Rankin Scale (mRS). The mRS is an ordinal scale ranging from 0 (no symptoms) to 6 (death). Scores 0-2 indicate functional independence, while scores 3-6 indicate functional dependence or death. Higher scores reflect worse clinical outcome.

    Time frame: Up to 30 days

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 20 observational studies under Status Epilepticus, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2026
First posted
Oct 1, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2027
CompletionEst.
Nov 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07853391
Lead sponsor
Assiut University
Responsible party
Hagar Khaled Abo Daif (Resident, Assiut University) — Principal investigator
First posted
Oct 1, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Oct 1, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion